Melanotan
Melanotan I — known generically as afamelanotide — is a synthetic 13-amino-acid peptide and a structural analogue of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring hormone that serves as the body's primary signal for melanin production. Originally developed at the University of Arizona in the 1980s from the hypothesis that inducing the body's own pigmentary system before UV exposure could reduce skin cancer rates, afamelanotide was designed to be more potent and enzymatically resistant than natural α-MSH — capable of stimulating melanogenesis independent of UV radiation.
Overview
Afamelanotide has a documented clinical history unlike most compounded peptides. It is the active ingredient in Scenesse®, approved by the European Medicines Agency in 2016 and the U.S. Food and Drug Administration in 2019 for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP) — a rare inherited disorder in which patients experience severe burning pain from even brief light exposure. In that indication, the clinical evidence base is robust, including multiple Phase III randomized controlled trials.
When used for cosmetic melanogenesis support, tanning, and UV photoprotection in individuals without EPP, the application is off-label. In this context, Melanotan I is prescribed by providers as part of supervised skin health and photoprotection protocols, often for patients with fair skin phenotypes and high UV exposure histories who seek to build protective pigment with or without significant sun exposure.
Afamelanotide (Melanotan I) Specifications
| Component | Detail |
|---|---|
| Afamelanotide (Melanotan I) | 10 mg lyophilized powder per vial |
| Reconstitution diluent | Bacteriostatic water for injection, 5 mL |
| Working concentration | 2 mg/mL post-reconstitution |
| Loading dose | 15 units (0.15 mL) = 300 mcg subcutaneously, once daily |
| Maintenance dose | 25 units (0.25 mL) = 500 mcg subcutaneously, per provider schedule |
Concentration: 10 mg / vial (lyophilized)
Reconstitution: 5 mL bacteriostatic water → 2 mg/mL working solution
Route: Subcutaneous injection
Available: 10 mg lyophilized vial with bacteriostatic water diluent
This compound requires a valid prescription from a licensed healthcare provider. When used for melanogenesis support and photoprotection in the general population, this application is off-label. Afamelanotide is FDA-approved under the brand name Scenesse® for erythropoietic protoporphyria (EPP) only.
Mechanism of Action
MC1R Agonism and the Melanogenesis Cascade Afamelanotide works by binding selectively and with high affinity to the melanocortin-1 receptor (MC1R), a G protein-coupled receptor expressed on melanocytes — the pigment-producing cells of the skin. MC1R is the primary receptor governing melanin synthesis. Afamelanotide's binding affinity for MC1R is significantly greater than that of natural α-MSH, and its resistance to proteolytic degradation extends its duration of receptor activation considerably.
When afamelanotide binds MC1R, it activates adenylate cyclase via G protein coupling, increasing intracellular cyclic AMP (cAMP). Elevated cAMP activates cAMP-dependent protein kinase (PKA), which phosphorylates the transcription factor CREB. Phosphorylated CREB binds to the cAMP response element on the microphthalmia-associated transcription factor (MITF) gene, driving MITF expression. MITF in turn activates the genes encoding the key melanogenic enzymes — tyrosinase, TYRP1, and DCT — increasing their concentration within the melanocyte and shifting melanin production decisively toward eumelanin.
This cascade is the same one triggered by UV exposure in the natural tanning response, but afamelanotide initiates it without requiring UV-induced DNA damage as the upstream signal.
Eumelanin vs. Pheomelanin
Why the Distinction Matters Not all melanin is equal in its photoprotective capacity. Melanocytes produce two forms: eumelanin (brown/black) and pheomelanin (red/yellow). Eumelanin is the photoprotective form — it absorbs UV radiation broadly across the spectrum, acts as a physical neutral-density filter, and scavenges UV-induced reactive oxygen species (ROS). Pheomelanin, by contrast, provides substantially less UV protection and may actually generate ROS under UV exposure.
UV-Independent Pigmentation
Critically, afamelanotide stimulates eumelanogenesis without requiring UV exposure as a prerequisite. This means patients can develop meaningful photoprotective pigment before sun exposure rather than in response to UV-induced cellular damage — the mechanistic basis for its utility as a proactive photoprotection strategy.
Antioxidant, DNA Repair, and Immunomodulatory Effects
MC1R activation by afamelanotide triggers additional protective signaling beyond melanin synthesis. These include upregulation of antioxidant defense pathways, enhancement of DNA repair activity (reducing the burden of UV-induced photoproducts such as thymine dimers), and secretion of immunomodulatory proteins including interleukin-10. Clinical studies have documented a reduction in epidermal sunburn cells and significant decreases in thymine dimer formation following afamelanotide administration — evidence of direct DNA-protective activity beyond the physical UV-blocking effect of eumelanin itself.
Simple. Medical. Personalized.
Medical intake
Answer a few online questions about your health history, lifestyle, and goals — no clinic visits required.
Provider evaluation
A licensed medical professional reviews your intake and determines the safest, most effective option for you.
Personalized plan
Custom treatment plan built around your unique health needs, goals, medical history, and biology.
Ongoing support
Stay connected with your care team for follow-ups, adjustments, and expert answers — all online.
FAQs
Dosage & Administration
Dosing follows a two-phase protocol adjusted based on individual pigmentation response. Do not adjust your dose without consulting your prescribing provider.
Phase 1 — Loading (Weeks 1–2): 15 units (0.15 mL = 300 mcg) subcutaneously, once daily. This initial lower dose allows for gradual melanocyte stimulation and individual tolerability assessment before escalating.
Phase 2 — Maintenance (Week 2+): 25 units (0.25 mL = 500 mcg) subcutaneously, once weekly. Frequency and dose are adjusted by your provider based on the degree of pigment change achieved and desired level of ongoing photoprotection.
Dose adjustment: Pigment response varies by individual skin type and baseline MC1R activity. Fair-skinned individuals (Fitzpatrick types I–II) with naturally lower MC1R expression may respond more slowly. Providers will adjust dosing intervals and duration based on your skin response during follow-up.
Reconstitution Instructions:
Allow the lyophilized vial to reach room temperature.
Draw 5 mL of bacteriostatic water into the provided syringe.
Insert the needle into the vial and inject the diluent slowly down the inner wall — do not inject directly onto the powder cake.
Gently swirl to dissolve. Do not shake.
The reconstituted solution should be clear and colorless. Discard if cloudy, discolored, or particulate matter is present.
Withdraw the prescribed dose volume for injection.
Swab the injection site with an alcohol wipe and allow to dry.
Administer subcutaneously in the abdomen or upper thigh. Rotate injection sites with each dose.
Precautions and Safety Information
Off-label use of afamelanotide for melanogenesis support in the general population has not been approved by the FDA. All use outside of the EPP indication is investigational. Patients should provide informed consent before initiating therapy.
Contraindications and Caution:
History of melanoma or dysplastic nevus syndrome: This is the most important contraindication for Melanotan I in a cosmetic or photoprotection context. Afamelanotide stimulates melanocyte proliferation and eumelanin production. Published case reports have documented changes to pre-existing moles following use of melanocortin analogs, including darkening, size increase, and in some cases histopathological dysplasia. Patients with a personal or family history of melanoma, atypical mole syndrome, or numerous pre-existing moles should not use this compound without dermatology consultation and careful risk-benefit assessment.
Mole monitoring requirement: All patients on Melanotan I should perform regular self-skin examination and have baseline and periodic dermatological evaluation, including dermoscopy of pre-existing lesions. Any change in size, shape, color, or border of a mole during treatment should prompt immediate evaluation and temporary discontinuation pending provider review.
Liver or kidney impairment: The metabolism and excretion of afamelanotide are not fully characterized. Caution is warranted in patients with hepatic or renal impairment, and use requires individualized provider assessment.
Pregnancy and breastfeeding: Safety data is absent. Use is not recommended.
Pediatric use: Not studied in patients under 18. Safety and dosing are unknown.
Benzyl alcohol sensitivity: The bacteriostatic water diluent contains 0.9% benzyl alcohol. Patients with known sensitivity should not use this formulation.
Potential Side Effects: The side effect profile of afamelanotide is well-characterized from EPP clinical trial data at the 16 mg implant dose. At the lower injectable doses used in photoprotection protocols, the following have been reported:
Nausea: The most commonly reported systemic side effect; typically mild and transient, most common after initial doses
Headache: Reported frequently in clinical trials; generally resolves without intervention
Injection site reactions: Transient redness, swelling, or bruising at the injection site
Flushing: Skin warmth or redness, particularly shortly after injection
Fatigue: Reported occasionally, typically in the early loading phase
Mole changes: Darkening of pre-existing moles and freckles; any new, changing, or atypical lesions must be reported to your provider immediately
What distinguishes Melanotan I from Melanotan II: Melanotan I binds selectively to MC1R. Melanotan II is a shorter, cyclized analog that additionally activates MC3R and MC4R — producing sexual arousal, spontaneous erections, appetite suppression, and a broader adverse effect profile. These off-target effects are not associated with Melanotan I at therapeutic doses.
Seek immediate care if you experience: any rapidly changing mole or new pigmented lesion, signs of a systemic allergic reaction (hives, difficulty breathing, facial swelling), or unusual symptoms following injection.
Drug Interactions
Formal drug interaction studies for compounded Melanotan I at these doses are limited. The following apply based on mechanism and available data:
Photosensitizing agents: Patients taking drugs that increase photosensitivity (certain antibiotics, diuretics, antifungals, NSAIDs, retinoids) should discuss this with their provider. Afamelanotide increases melanin-mediated photoprotection; however, the interaction with drug-induced photosensitivity has not been formally studied.
Immunosuppressants: Afamelanotide has been studied specifically in organ transplant recipients (who are on immunosuppressive regimens) for prevention of actinic keratosis and squamous cell carcinoma — a setting where its anti-carcinogenic and photoprotective effects are considered particularly valuable. No adverse interactions with standard immunosuppressive regimens were identified in those trials, but provider coordination is essential in this population.
Melanoma-targeted therapies: Afamelanotide should not be used concurrently with BRAF inhibitors, MEK inhibitors, or checkpoint immunotherapy without explicit oncology guidance, given the shared biological pathways involving melanocyte activity.
No significant interactions with commonly compounded peptide therapies, hormones, or vitamins have been identified.
Storage
Before reconstitution (lyophilized vial):
Refrigerate at 36°F – 46°F (2°C – 8°C)
Protect from light; store in original packaging
Do not freeze
Use before labeled expiration date
After reconstitution (bacteriostatic water):
Refrigerate at 36°F – 46°F (2°C – 8°C)
Use within 28 days of reconstitution
Keep vial capped and protected from light
Discard if solution becomes cloudy, discolored, or shows particulate matter
How It Works
FAQs
© 2026, TestosteroneShots.com PC
text (323)-283-9219
638 1/2 N Robertson Blvd, West Hollywood, CA 90069
The information and products provided on this website are for informational and wellness purposes only and are not intended to diagnose, treat, cure, or prevent any disease. All medical treatments are subject to evaluation and approval by a licensed healthcare provider through a telemedicine consultation. Individual results may vary, and the use of any product carries potential risks and side effects that should be discussed with a qualified medical professional. These products are not approved by the FDA unless explicitly stated, and misuse or unauthorized sharing is strictly prohibited. By using this site or purchasing any service, you agree to our Terms of Service, Telehealth Consent, and Privacy Policy. We prioritize your privacy and comply with HIPAA regulations for protected health information. Services provided by licensed physicians/nurse practitioners in states served, e.g., CA, FL, and others, via telemedicine. Check your state's telemedicine laws. Must Be 18+ or Older to Qualify For Treatment.
